Article Figures & Data
Figures
- Figure 1.
Efficacy of NOACS Versus Warfarin in Clinical Trials
On December 11, 2014, this figure was changed to the correct figure. Data are n/N, unless otherwise indicated. Heterogeneity: I 2 = 47%; P = .13. NOAC, novel oral anticoagulant. *Dabigatran 150 mg twice daily. † Rivaroxaban 20 mg once daily. ‡ Apixaban 5 mg twice daily. ∫ Edoxaban 60 mg once daily.
Reprinted from Ruff CT et al, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383:955–962. Copyright © 2014, with permission from Elsevier.
- Figure 2.
Risk of GI Bleeding With Antithrombotics or NSAIDs
ASA, aspirin; NSAID, nonsteroidal anti-inflammatory drug.
Reproduced from Delaney JA et al. Drug—drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007;177:347–51. With permission from Canadian Medical Association.
The editors would like to thank the many members of the 2014 European Society of Cardiology presenting faculty who generously gave their time to ensure the accuracy and quality of the articles in this publication.
Tools
Table of contents
Cited By...
- No citing articles found.